靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用

doi:10.3760/cma.j.issn.1673-422X.2014.02.011

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (2): 113-116.doi: 10.3760/cma.j.issn.1673-422X.2014.02.011

靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用

周宁, 朱远, 罗加林

310022 杭州，浙江省肿瘤医院放疗科

收稿日期:2013-09-09 修回日期:2013-12-02 出版日期:2014-02-08 发布日期:2014-01-26
通讯作者: 朱远，E-mail: zhuyuan63@hotmail.com E-mail:zhuyuan63@hotmail.com

Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Zhou Ning, Zhu Yuan, Luo Jialin

Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China

Received:2013-09-09 Revised:2013-12-02 Online:2014-02-08 Published:2014-01-26
Contact: Zhu Yuan E-mail:zhuyuan63@hotmail.com

摘要/Abstract

摘要： 目前新辅助放化疗联合全直肠系膜切除术（TME）是局部进展期直肠癌（LARC）的标准治疗模式。靶向药物在LARC新辅助治疗中耐受性及安全性良好，但与常规新辅助放化疗相比较，病理完全缓解（pCR）率并无提高，仍需大样本随机对照研究证实其在LARC新辅助治疗中的作用。

关键词: 直肠肿瘤, 受体, 表皮生长因子, 受体, 血管内皮生长因子, 肿瘤辅助疗法

Abstract: Neoadujuvant chemoradiotherapy combined with total mesorectal excision (TME) is the standard treatment modality for locally advanced rectal cancer (LARC). Targeted drugs in LARC neoadjuvant therapy are well tolerated and safety, but compared with conventional neoadjuvant chemoradiotherapy, the pathologic complete response (pCR) rate is not increased. Large sample randomized controlled trials are needed to confirm the effects of targeted drugs in the neoadjuvant treatment of LARC.

Key words: Rectal neoplasms, Receptor, epidermal growth factor, Receptors, vascular endothelial growth factor, Neoadjuvant therapy

周宁, 朱远, 罗加林. 靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用[J]. 国际肿瘤学杂志, 2014, 41(2): 113-116.

Zhou Ning, Zhu Yuan, Luo Jialin. Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2014, 41(2): 113-116.

参考文献

［1］ Huerta S. New directions in the preoperative management of adenocarcinoma of the rectum［J］. Crit Rev Oncog, 2012, 17(4)：393-396. ［2］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4)：1171-1178. ［3］ Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with singleagent cetuximab followed by 5FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2009, 73 (2)：466-472. ［4］ Velenik V, Ocvirk J, Oblak I, et al. A phase Ⅱ study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer［J］. Eur J Surg Oncol, 2010, 36(3)：244-250. ［5］ Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study［J］. Int J Colorectal Dis, 2012, 27(10)：1325-1332. ［6］ Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer (EXPERTC)［J］. J Clin Oncol, 2012, 30(14)：1620-1627. ［7］ Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3)：677-683. ［8］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7)：1535-1546. ［9］ Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer［J］. J Clin Oncol, 2009, 27(17)：2751-2757. ［10］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4)：1032-1038. ［11］ Zhu Y, Liu LY, Luo JL, et al. Preoperative chemoradiation with nimotuzumab and capecitabine in patients with locally advanced rectal cancer: a phase Ⅱ study［J］. J Clin Oncol 30, 2012 (suppl: abstr e14049). ［12］ Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase Ⅰ trial results［J］. J Clin Oncol, 2006, 24(4)：656-662. ［13］ Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5fluorouracil and ZD1839 (GefitinibIressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase Ⅰ and Ⅱ Trial (1839IL/0092)［J］. Int J Radiat Oncol Biol Phys, 2008, 72(3)：644-649. ［14］田源, 蔡欣, 刘基巍. 结肠直肠癌的分子靶向治疗进展［J］. 癌症进展, 2010, 8(2)：151-155, 179. ［15］ Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase Ⅱ study［J］. J Clin Oncol, 2009, 27(18)：3020-3026. ［16］ Crane CH, Eng C, Feig BW, et al. Phase Ⅱ trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3)：824-830. ［17］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imagingdefined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5)：614-620. ［18］ Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an openlabel phase Ⅱ study［J］. Radiat Oncol, 2011, 6：105. ［19］ Kennecke H, Berry S, Wong R, et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase Ⅱ trial［J］. Eur J Cancer, 2012, 48(1)：37-45. ［20］ Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND2 study［J］. J Clin Oncol, 2007, 25(29)：4557-4561. ［21］ Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase Ⅲ study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in firstline advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity［J］. Ann Oncol, 2008, 19(4)：734-738. ［22］ Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase ⅢB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer［J］. J Clin Oncol, 2009, 27(5)：672680. ［23］ Wong NS, Fernando NH, Nixon AB ,et al. A phase Ⅱ study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer［J］. Anticancer Res, 2011, 31(1)：255-261.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[5]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[13]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[14]	徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[15]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.

靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用

Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价